Defined scientific target
Formal work makes the requirements and limits of a prospective-health question explicit. Explore the canonical papers ↗
Fieldflux Biosystems · Investor overview
Health, formally defined. Measurement, engineered.
Fieldflux is developing software and instruments around a formal scientific definition of health. The commercial program brings together an available consumer application, patent-pending measurement architecture, and a staged path toward stronger physical and empirical evidence.
What differentiates the approach
A definition creates the question. Engineering makes it observable.
The published formal-health research establishes a rigorous way to state prospective health and the information needed to answer declared health questions. Fieldflux develops the physical sensing, acquisition, calibration, and software needed to investigate practical applications.
Protected implementation
Patent-pending sensing and response-measurement systems address source witness, timing, calibration, distributed acquisition, and evidence provenance.
Product and validation pathway
Membrane Health is available. Research hardware, repeatability studies, and clinical translation form distinct development steps with separate evidence requirements.
Present state and development horizons
What exists. What is being tested. What comes next.
Each program is shown at its own maturity. Product availability, internal testing, research prototypes, and proposed clinical capabilities carry different evidentiary standards.
Membrane Health
Available in the App Store, bringing Apple Health measurements and personalized context into an ongoing physiological information experience.
DRTT 2.0
Distributed Real-Time Topology is in-house alpha testing for timing, coherence, route relationships, recovery, drift, and traceable acquisition.
Rev B Boundary Witness Instrument
A developing portable, battery-isolated, multi-node instrument designed for directly witnessed sources, calibrated fixtures, and physical measurement.
Bedside QPCI
A proposed higher-granularity multimodal instrument integrating distributed sensing with the workflow and reliability needed for bedside research.
Empirical validation and translational work
Studies and research collaborations develop the evidence needed for repeatability, physiological interpretation, usefulness, and progressively stronger claims. Clinical authority will depend on the outcomes of appropriate validation.
Capital and execution
The next capital advances the physical evidence.
The current development priority is Rev B, with complementary work on performance, calibration, pilot readiness, and the evidence infrastructure needed for further product and research milestones.
- Rev B build and engineering verification
- Calibration, repeatability and sensitivity
- Prospective measurements and research pilots
- Data quality, provenance and validation systems
- Manufacturing and reliability preparation
- Development milestones and translational readiness
The roadmap identifies development objectives, not completed clinical capabilities or guaranteed schedules. Investor materials provide the detailed operating plan and financing information.
Evidence and scientific scope
Claims grow with the quality of their evidence.
Machine-checked mathematical results establish consequences of a declared formal specification. Physical measurement requires source, timing, calibration, provenance, and uncertainty controls. Clinical claims require their own empirical evidence and evaluation.
Fieldflux's current products and developing instruments are presented according to these different levels of authority.
Investor inquiries
Request the investor materials.
Qualified investors may request the technical brief, patent and IP overview, business plan, development milestones, financial information, and supporting materials. Access to confidential information is arranged directly.